Turning cell cycle controller genes into cancer drugs: A role for an antiproliferative cytokine (βGBP)

Biochemical Pharmacology

Volumn 66, Issue 8, 2003, Pages 1563-1569

  Mallucci, Livio ^a   Wells, Valerie ^a   Danikas, Antonios ^a   Davies, Derek ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

galactoside binding protein; GBP; Chronic myeloid leukaemia; CML; E2 promoter binding factor; E2F; IAP; MAPK; Mitogen activated protein kinase; PDGF; PKB; Platelet derived growth factor; Protein kinase B; Receptor tyrosine kinase; RTK

Indexed keywords

ANTINEOPLASTIC AGENT; GALAPTIN; TRANSCRIPTION FACTOR E2F1; CELL CYCLE PROTEIN; CYTOKINE; DNA BINDING PROTEIN; E2F1 PROTEIN, HUMAN; GALECTIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; BREAST CANCER; CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE S PHASE; CELL KILLING; CONFERENCE PAPER; DOWN REGULATION; DRUG TARGETING; GENE; GENE FUNCTION; GENETIC DIFFERENCE; GROWTH DISORDER; HUMAN; INHIBITION KINETICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; ANIMAL; B CELL LYMPHOMA; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL DIVISION; CYTOKINES; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GALECTINS; GENES, CDC; HUMANS; LYMPHOMA, B-CELL; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0642314378     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00512-4     Document Type: Conference Paper

References (61)

1. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:2002;153-164.
2. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science. 278:1997;1064-1068.
3. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science. 287:2000;1969-1973.
4. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
5. Sebti S.M., Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19:2000;6584-6593.
6. Baell J.B., Huang D.C. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 64:2002;851-863.
7. Cox A.D., Der C.J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2:2002;388-393.
8. Sawyers C.L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12:2002;111-115.
9. Singh S.B., Lingham R.B. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug Discov. Dev. 5:2002;225-244.
10. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:2003;11-22.
11. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell. 3:2003;17-22.
12. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/ abl hybrid gene. Science. 233:1986;212-214.
13. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082.
14. Bedi A., Zehnbauer B.A., Barber J.P., Sharkis S.J., Jones R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:1994;2038-2044.
15. Puil L., Liu J., Gish G., Mbamalu G., Bowtell D., Pelicci P.G., Arlinghaus R., Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:1994;764-773.
16. Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidransky D., Vala M.S., Akhtar A.J., Hilton J., Jones R.J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 86:1995;1148-1158.
17. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
18. Mauro M.J., Druker B.J. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 6:2001;233-238.
19. Weisberg E., Griffin J.D. Mechanisms of resistance to imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist. Update. 4:2001;22-28.
20. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:2002;331-341.
21. Wells V., Mallucci L. Identification of an autocrine negative growth factor: mouse beta-galactoside-binding protein is a cytostatic factor and cell growth regulator. Cell. 64:1991;91-97.
22. Wells V., Mallucci L. Molecular expression of the negative growth factor murine beta-galactoside binding protein (mGBP). Biochim. Biophys. Acta. 1121:1992;239-244.
23. Chiariotti L., Wells V., Bruni C.B., Mallucci L. Structure and expression of the negative growth factor mouse beta-galactoside binding protein gene. Biochim. Biophys. Acta. 1089:1991;54-60.
24. Baldini A., Gress T., Patel K., Muresu R., Chiariotti L., Williamson P., Boyd Y., Casciano I., Wells V., Bruni C.B., Mallucci L., Siniscalco M. Mapping on human and mouse chromosomes of the gene for the beta-galactoside-binding protein, an autocrine-negative growth factor. Genomics. 15:1993;216-218.
25. Aurias A., Rimbaut C., Buffe D., Zucker J.M., Mazabraud A. Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet. Cytogenet. 12:1984;21-25.
26. Turc-Carel C., Dal Cin P., Rao U., Karakousis C., Sandberg A.A. Recurrent breakpoints at 9q31 and 22q12.2 in extraskeletal myxoid chondrosarcoma. Cancer Genet. Cytogenet. 30:1988;145-150.
27. Bridge J.A., Borek D.A., Neff J.R., Huntrakoon M. Chromosomal abnormalities in clear cell sarcoma. Implications for histogenesis. Am. J. Clin. Pathol. 93:1990;26-31.
28. Rey J.A., Bello M.J., de Campos J.M., Vaquero J., Kusak M.E., Sarasa J.L., Pestana A. Abnormalities of chromosome 22 in human brain tumors determined by combined cytogenetic and molecular genetic approaches. Cancer Genet. Cytogenet. 66:1993;1-10.
29. Blaser C., Kaufmann M., Muller C., Zimmermann C., Wells V., Mallucci L., Pircher H. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol. 28:1998;2311-2319.
30. Wells V., Mallucci L. A new approach to breast cancer control. Turning cell cycle controller genes into cancer drugs. Br. J. Cancer. 86:2002;85.
31. Allione A., Wells V., Forni G., Mallucci L., Novelli F. β Galactoside binding protein alters the cell cycle, upregulates expression of the α and β chains of the IFNγ receptor and promotes IFNγ mediated apoptosis of activated human T lymphocytes. J. Immunol. 161:1998;2114-2119.
32. Mallucci L., Wells V. Negative control of cell proliferation. Growth arrest vs. apoptosis. J. Theor. Med. 1:1998;169-173.
33. Novelli F., Allione A., Wells V., Forni G., Mallucci L. Negative cell cycle control of human T cells by beta-galactoside binding protein (beta GBP): induction of programmed cell death in leukaemic cells. J. Cell Physiol. 178:1999;102-108.
34. Wells V., Davies D., Mallucci L. Cell cycle arrest and induction of apoptosis by beta galactoside binding protein (beta GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur. J. Cancer. 35:1999;978-983.
35. Teixeira C., Reed J.C., Pratt M.A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:1995;3902-3907.
36. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953.
37. Makin G., Hickman J.A. Apoptosis and cancer chemotherapy. Cell Tissue Res. 301:2000;143-152.
38. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
39. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature. 411:2001;342-348.
40. Green D.R., Evan G.I. A matter of life and death. Cancer Cell. 1:2002;19-30.
41. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2:2002;183-192.
42. Reed J.C. Apoptosis-based therapies. Nat. Rev. Drug Discov. 1:2002;111-121.
43. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
44. Haupt Y., Robles A.I., Prives C., Rotter V. Deconstruction of p53 functions and regulation. Oncogene. 21:2002;8223-8231.
45. Hartwell L.H., Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science. 246:1989;629-634.
46. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 71:1992;543-546.
47. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
48. Krek W., Ewen M.E., Shirodkar S., Arany Z., Kaelin W.G. Jr., Livingston D.M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 78:1994;161-172.
49. Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science. 274:1996;1664-1672.
50. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
51. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 8:1998;28-35.
52. Shan B., Lee W.H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell Biol. 14:1994;8166-8173.
53. Krek W., Xu G., Livingston D.M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83:1995;1149-1158.
54. Fueyo J., Gomez-Manzano C., Yung W.K., Liu T.J., Alemany R., McDonnell T.J., Shi X., Rao J.S., Levin V.A., Kyritsis A.P. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 4:1998;685-690.
55. Liu T.J., Wang M., Breau R.L., Henderson Y., El-Naggar A.K., Steck K.D., Sicard M.W., Clayman G.L. Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. Cancer Gene Ther. 6:1999;163-171.
56. Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E., Cecconi F., Muller H., Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 3:2001;552-558.
57. Nahle Z., Polakoff J., Davuluri R.V., McCurrach M.E., Jacobson M.D., Narita M., Zhang M.Q., Lazebnik Y., Bar-Sagi D., Lowe S.W. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 4:2002;859-864.
58. Martins L.M., Iaccarino I., Tenev T., Gschmeissner S., Totty N.F., Lemoine N.R., Savapoulos J., Gray C.W., Creasy C.L., Dingwall C., Downward J. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a Reaper-like motif. J. Biol. Chem. 277:2002;439-444.
59. Bargou R.C., Wagener C., Bommert K., Arnold W., Daniel P.T., Mapara M.Y., Grinstein E., Royer H.D., Dorken B. Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J. Exp. Med. 183:1996;1205-1213.
60. 1 transition by the betaGBP cytokine. Inhibition of Ras-MAPK signaling is preceded by loss of PI3K activity. In: Keystone Symposium, Cell Response to Lipid Mediators, Taos, USA; 2-6 February 2002. p. 27.
61. Li X., Darzynkiewicz Z. Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif. 28:1995;571-579.